For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 42,651 | 44,831* | 37,480 | 33,558 |
| General and administrative | 11,464 | 12,372* | 9,378 | 9,052 |
| Total operating expenses | 54,115 | 57,203 | 46,858 | 42,610 |
| Loss from operations | -54,115 | -57,203* | -46,858 | -42,610 |
| Interest income | 5,102 | 4,581 | 6,192 | 6,495 |
| Total other income | 5,102 | 4,581* | 6,192 | 6,495 |
| Net loss | -49,013 | -52,623* | -40,666 | -36,115 |
| Unrealized gain on available-for-sale securities, net | -929 | -193* | 497 | -197 |
| Total comprehensive loss | -49,942 | -52,816 | -40,169 | -36,312 |
| Basic EPS | -0.46 | -0.537 | -0.39 | -0.34 |
| Diluted EPS | -0.46 | -0.537 | -0.39 | -0.34 |
| Basic Average Shares | 107,116,709 | 98,358,960 | 105,492,779 | 104,940,493 |
| Diluted Average Shares | 107,116,709 | 98,358,960 | 105,492,779 | 104,940,493 |
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)